Academic Journal
Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
| العنوان: | Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial |
|---|---|
| المؤلفون: | Chandran, Vinod, Malkov, Vladislav A, Ito, Kaori L, Liu, Yihua, Vestergaard, Lene, Yoon, Oh Kyu, Liu, Jinfeng, Trivedi, Mona, Hertz, Angie, Gladman, Dafna |
| المساهمون: | Galápagos, Gilead Sciences |
| المصدر: | RMD Open ; volume 9, issue 4, page e003550 ; ISSN 2056-5933 |
| بيانات النشر: | BMJ |
| سنة النشر: | 2023 |
| الوصف: | Objectives The goal of this study was to identify protein and transcriptional biomarkers and pathways associated with baseline disease state, the effect of filgotinib (FIL) treatment on these biomarkers, and to investigate the mechanism of action of FIL on clinical improvement in patients with active psoriatic arthritis (PsA). Methods The phase II EQUATOR ( NCT03101670 ) trial evaluated the efficacy of FIL, a Janus kinase 1-preferential inhibitor, in patients with PsA. Peripheral protein and gene expression levels in association with clinical state at baseline and post-treatment were assessed in 121 patients using linear mixed effects models for repeated measures analyses. Mediation analysis and structural equation modelling (SEM) were performed to investigate the mechanism of action of FIL at week 4 on downstream clinical improvement at week 16. Results Baseline analyses showed that markers of inflammation were significantly associated with multiple PsA clinical metrics, except for Psoriasis Area and Severity Index (PASI), which corresponded to Th17 markers. FIL treatment resulted in sustained transcriptional inhibition of immune genes and pathways, a sustained increase in B-cell fraction and mature B-cells in circulation, and a transient effect on other cell fractions. Mediation analysis revealed that changes in B cells, systemic inflammatory cytokines and neutrophils at week 4 were associated with changes in clinical metrics at week 16. SEM suggested that FIL improved PASI through reduction of IL-23 p19 and IL-12 p40 proteins. Conclusions Our results revealed that FIL treatment rapidly downregulates inflammatory and immune pathways associated with PsA disease activity corresponding to clinical improvement in PsA. Trial registration number NCT03101670 . |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1136/rmdopen-2023-003550 |
| الاتاحة: | http://dx.doi.org/10.1136/rmdopen-2023-003550 https://syndication.highwire.org/content/doi/10.1136/rmdopen-2023-003550 |
| Rights: | http://creativecommons.org/licenses/by-nc/4.0/ |
| رقم الانضمام: | edsbas.585A77F1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/rmdopen-2023-003550 |
|---|